NO924073L - Anvendelse av gm-csf og g-csf for aa fremme fremskyndet saarheling - Google Patents

Anvendelse av gm-csf og g-csf for aa fremme fremskyndet saarheling

Info

Publication number
NO924073L
NO924073L NO92924073A NO924073A NO924073L NO 924073 L NO924073 L NO 924073L NO 92924073 A NO92924073 A NO 92924073A NO 924073 A NO924073 A NO 924073A NO 924073 L NO924073 L NO 924073L
Authority
NO
Norway
Prior art keywords
csf
application
specific health
promote specific
promote
Prior art date
Application number
NO92924073A
Other languages
English (en)
Other versions
NO924073D0 (no
Inventor
Glenn Pierce
Bruce W Altrock
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO924073L publication Critical patent/NO924073L/no
Publication of NO924073D0 publication Critical patent/NO924073D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
NO924073A 1991-02-22 1992-10-21 Anvendelse av gm-csf og g-csf for aa fremme fremskyndet saarheling NO924073D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65978091A 1991-02-22 1991-02-22
US82149892A 1992-01-21 1992-01-21
PCT/US1992/001245 WO1992014480A1 (en) 1991-02-22 1992-02-19 Use of gm-csf and g-csf to promote accelerated wound healing

Publications (2)

Publication Number Publication Date
NO924073L true NO924073L (no) 1992-10-21
NO924073D0 NO924073D0 (no) 1992-10-21

Family

ID=27097898

Family Applications (1)

Application Number Title Priority Date Filing Date
NO924073A NO924073D0 (no) 1991-02-22 1992-10-21 Anvendelse av gm-csf og g-csf for aa fremme fremskyndet saarheling

Country Status (11)

Country Link
US (1) US6689351B1 (no)
EP (1) EP0526630A4 (no)
JP (1) JPH05506673A (no)
AU (1) AU1462392A (no)
CA (1) CA2081104A1 (no)
FI (1) FI924778A0 (no)
IE (1) IE920560A1 (no)
IL (1) IL101028A0 (no)
NO (1) NO924073D0 (no)
PT (1) PT100152A (no)
WO (1) WO1992014480A1 (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824297A (en) * 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
US5817625A (en) * 1992-09-21 1998-10-06 Oncogene Science, Inc. Methods of prevention of oral mucositis with transforming growth factor beta
EP0663211A4 (en) * 1993-03-17 1997-07-09 Otsuka Pharma Co Ltd AGENT FOR PREVENTION AND TREATMENT OF DIGESTIVE APPARATUS MUCOUS DISORDERS.
SK281674B6 (sk) * 1993-03-26 2001-06-11 Amgen Inc. Farmaceutická kompozícia na stimuláciu hepatocytov, pneumocytov typu ii, pohárikovitých buniek produkujúcich mucín a iných epitelových buniek
US5965530A (en) * 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
US5578566A (en) * 1993-05-04 1996-11-26 The United States Of America As Represented By The Department Of Health And Human Services KGF receptor-derived antagonists of KGF binding
US5599788A (en) * 1994-07-01 1997-02-04 Advanced Tissue Sciences Method for accelerating skin wound healing with H3 protein
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
GB2304342A (en) * 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
AU747598B2 (en) * 1995-08-18 2002-05-16 Renovo Limited Pharmaceutical composition containing stimulators of interferon-gamma
IT1276213B1 (it) * 1995-10-06 1997-10-27 Mendes Srl Composizioni dermatologiche e cosmetiche atte all'applicazione topica, ad effetto modulante sulle ceramidi endogene dell'epidermide
ES2293137T3 (es) * 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
JP4891477B2 (ja) 1997-10-02 2012-03-07 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． 血管新生及び／または既存細動脈網から側枝動脈及び／または他の動脈の発達の調節に関する方法
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6238888B1 (en) 1997-12-22 2001-05-29 Human Genone Sciences, Inc. Keratinocyte growth factor-2 formulations
US6676937B1 (en) * 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
US7011965B2 (en) * 2001-03-09 2006-03-14 Regents Of The University Of Minnesota Compositions and methods for stimulating wound healing and fibroblast proliferation
EA007322B1 (ru) * 2001-04-18 2006-08-25 Прометик Байосайенсиз, Инк. Жирные кислоты со средней длиной цепи, глицериды и аналоги как факторы, способствующие выживанию и активации нейтрофилов
CA2464609A1 (en) * 2001-10-26 2003-05-01 University Technologies International, Inc. Use of egf to inhibit pathogenic infections of the urogenital tract
DE10154579A1 (de) * 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
CN100484569C (zh) * 2001-11-19 2009-05-06 协和发酵工业株式会社 将多潜能干细胞从组织中流通到外周血的药物
FR2834899B1 (fr) * 2002-01-18 2005-06-10 Didier Pourquier Nouvelle application therapeutique des facteurs g-csf, gm-csf et scf
US7048914B2 (en) 2002-12-12 2006-05-23 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
US7374754B2 (en) 2003-09-02 2008-05-20 Essential Skincare, Llc Use of placental alkaline phosphatase to promote skin cell proliferation
JPWO2005034986A1 (ja) * 2003-10-14 2006-12-21 中外製薬株式会社 腎疾患治療剤
EP1693065B1 (en) 2003-10-27 2012-12-26 Keio University Fibroblast-mobilizing agent containing g-csf and wound remedy
SE0400942D0 (sv) * 2004-04-08 2004-04-08 Henrik Arnberg Composition and method
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
MX2007000568A (es) * 2004-07-16 2007-03-30 Nektar Therapeutics Al Corp Conjugados de una fraccion gm-csf y un polimero.
CA2584553A1 (en) * 2004-09-17 2006-03-23 Cellgentech, Inc. External agent for treatment of skin ulcer
JP2006137747A (ja) * 2004-10-14 2006-06-01 Hayashibara Biochem Lab Inc サイトカイン類及び／又はケモカイン類産生増強剤
US20070003541A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
US20070128685A1 (en) * 2005-07-01 2007-06-07 Rodolfo Faudoa Methods and compositions for cell culture
US20070004036A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
EP2099495A2 (en) * 2005-08-04 2009-09-16 Nektar Therapeutics AL, Corporation Conjugates of a g-csf moiety and a polymer
GB0524103D0 (en) * 2005-11-26 2006-01-04 Medical Res Council Healing
WO2007075199A1 (en) 2005-12-28 2007-07-05 Zoltan Laboratories Llc Use of alkaline phosphatase to maintain healthy tissue mass in mammals
JPWO2007119486A1 (ja) 2006-03-22 2009-08-27 セルジェンテック株式会社 皮膚潰瘍治療のための外用液状組成物および外用製剤
WO2008005533A2 (en) * 2006-07-06 2008-01-10 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
US8673859B2 (en) 2007-03-20 2014-03-18 New York University GM-CSF cosmeceutical compositions and methods of use thereof
EP2036571A1 (de) 2007-09-13 2009-03-18 Sygnis Bioscience GmbH & Co. KG Verwendung von G-CSF für die Behandlung von Schlaganfall
JP5702150B2 (ja) 2008-02-08 2015-04-15 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾されているレプチンポリペプチドおよびそれらの使用
JP5680534B2 (ja) 2008-07-23 2015-03-04 イーライ リリー アンド カンパニー 修飾されているウシｇ−ｃｓｆポリペプチドおよびそれらの使用
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
US20120121547A1 (en) * 2010-09-16 2012-05-17 Wagner Donald J Methods and compositions for treating chronic wounds
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
CN106163542A (zh) * 2014-02-05 2016-11-23 雷波内制药有限公司 用于促进皮肤溃疡和伤口愈合的组合物
US20170182125A1 (en) * 2014-05-23 2017-06-29 Reponex Pharmaceuticals Aps Compositions for promoting the healing of wounds
WO2016012608A1 (en) 2014-07-24 2016-01-28 Reponex Pharmaceuticals Aps Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease
US9820953B2 (en) * 2016-02-26 2017-11-21 Omni Bioceutical Innovations, Inc. Compositions of bioactive fulvate fractions and uses thereof
CA3067064A1 (en) * 2017-06-14 2018-12-20 Mcmaster University Biomarkers for wound healing
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US5110604A (en) * 1988-06-30 1992-05-05 Collagen Corporation Processes for producing collagen matrixes and methods of using same
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
ATE89737T1 (de) * 1989-01-30 1993-06-15 Schering Corp Behandlung von leukozytstoerungen mit gm-csf.
EP0463037A1 (en) * 1989-03-17 1992-01-02 Genetics Institute, Inc. Human macrophage migration inhibitory factor

Also Published As

Publication number Publication date
IE920560A1 (en) 1992-08-26
EP0526630A4 (en) 1993-08-11
FI924778A (fi) 1992-10-21
AU1462392A (en) 1992-09-15
JPH05506673A (ja) 1993-09-30
PT100152A (pt) 1993-05-31
WO1992014480A1 (en) 1992-09-03
IL101028A0 (en) 1992-11-15
NO924073D0 (no) 1992-10-21
US6689351B1 (en) 2004-02-10
CA2081104A1 (en) 1992-08-23
EP0526630A1 (en) 1993-02-10
FI924778A0 (fi) 1992-10-21

Similar Documents

Publication Publication Date Title
NO924073L (no) Anvendelse av gm-csf og g-csf for aa fremme fremskyndet saarheling
DK451388A (da) Terapeutisk nucleosider og farmaceutiske kompositioner indeholdende forbindelserne
NO172904C (no) Legeringer og anvendelse av disse
EP0532466A3 (en) Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
DK127787D0 (da) Interleukin-1alfa-derivater og medikamenter indeholdende saadanne derivater
DK475684A (da) Phenothiazinderivater og farmaceutiske praeparater indeholdende phenothiazinderivaterne
HU9202085D0 (en) Derivatives of 7-isoindolinyl-quinolone and of naphthyridone-carboxylic acid
NO165494C (no) Aminosalter av lignosulfonater og anvendelse derav.
KR880700673A (ko) 골손상 치료용방법 및 조성물
NO941163D0 (no) Behandling av kjött
DK497685D0 (da) Ketongruppeholdige oxindol-3-carboxamid-derivater og laegemiddel indeholdende saadanne derivater
NO823084L (no) Addisjonsprodukter av trietanolaminkodensater og bis-glycidyletere og deres anvendelse
NO940027L (no) Fremgangsmaate for fremstilling av derivater av B-fenylisorerin og derivatenes anvendelse
FI924360A (fi) Enfasigt foerfarande foer framstaellning av diritromycin
NO882462L (no) Fremstilling og bruk av fenolderivater.
NO862729L (no) Diazinylpiperidinderivater av cykliske amider og imider.
NO854945L (no) Fremgangsmaate for desinfeksjon av jordolje og jordoljeprodukter.
DK360884D0 (da) Farmaceutiske og veterinaere midler til behandling af iskaemiskehjertelidelser
DK0512547T3 (da) Smertekontrollerende præparat og fremgangsmåde til fremstilling deraf
DK406384D0 (da) Imidazobenzodiazepinderivater og disses anvendelse
NO952261D0 (no) Antacidiumforbindelser og fremgangsmåte for fremstilling derav
NO924390D0 (no) Fremgangsmaate og system for fremskaffelse av volumgjengivelse
DK60187D0 (da) Bis-diozopiperazin-derivater og laegemiddelformuleringer indeholdende saadanne forbindelser
NO933076L (no) Næringssammensetning og fremgangsmåte for fremstilling
NO179049C (no) Profilplate bestående av bærende og romavsluttende avsnitt